公开(公告)号：US11492402B2

公开(公告)日：2022-11-08

申请号：US16601070

申请日：2019-10-14

Applicant: NOVARTIS AG

Inventor： Verena Brand ,  Dominik Feuerbach ,  Fabrizio Gasparini ,  Nathalie George ,  Eveline Schaadt ,  Derya Shimshek ,  Honnappa Srinivas ,  Markus Waldhuber ,  Rainer Wilcken

IPC: C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  A61K39/00 ,  C12N7/00 ,  C12N15/70

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US10722518B2

公开(公告)日：2020-07-28

申请号：US15730175

申请日：2017-10-11

Applicant: Novartis AG

Inventor： Cristina Lopez-Lopez ,  Ulf Neumann ,  Derya Shimshek

IPC: A61K31/5377 ,  A61P9/10

Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.